Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564309 | 0.91 | CYP2C19 (0.56) | FABP7FABP5CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL13452120 | 0.91 | CYP2C19 (0.56) | FABP7FABP5CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL16001109 | 0.91 | CYP2C19 (0.56) | FABP7FABP5CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL280126 | 0.88 | FABP7 (0.58) | FABP7FABP5CYP2C19HPGDSMN1; SMN2 | |
| SCHEMBL10917021 | 0.88 | FABP7 (0.58) | FABP7FABP5CYP2C19HPGDSMN1; SMN2 | |
| SCHEMBL6666657 | 0.88 | FABP7 (0.58) | FABP7FABP5CYP2C19HPGDSMN1; SMN2 | |
| SCHEMBL17365604 | 0.88 | CYP3A4 (0.53) | FABP7FABP5CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL11982183 | 0.88 | CYP3A4 (0.53) | FABP7FABP5CYP2C19CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL27944947 | 0.86 | FABP7 (0.57) | FABP7FABP5CYP2C19HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27765522 | 0.86 | FABP7 (0.57) | FABP7FABP5CYP2C19HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865889-A | Synthesis method of benzisoquinoline compound | 山东省药学科学院 | 2024-04-12 | — | — | CN | claimed |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| US-20250223289-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | SCHRODINGER, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-02-18 | — | — | US | disclosed |
| US-12145935-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-117865889-A | Synthesis method of benzisoquinoline compound | 山东省药学科学院 | 2024-04-12 | — | — | CN | disclosed |
| US-20110274655-A1 | TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE | Infinity Pharmaceuticals (US) | 2011-11-10 | — | — | US | disclosed |
| US-7816380-B2 | 1-hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1758949-B1 | POLYHYDROXYALKANOATE HAVING VINYL GROUP, ESTER GROUP, CARBOXYL GROUP AND SULFONIC ACID GROUP, AND PRODUCTION METHOD THEREOF | CANON KK (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2009-03-05 | — | — | US | disclosed |
| US-7465779-B2 | Polyhydroxyalkanoate having vinyl group, ester group, carboxyl group and sulfonic acid group, and production method thereof | CANON KABUSHIKI KAISHA (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1893579-A1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1758949-A2 | POLYHYDROXYALKANOATE HAVING VINYL GROUP, ESTER GROUP, CARBOXYL GROUP AND SULFONIC ACID GROUP, AND PRODUCTION METHOD THEREOF | Canon Kabushiki Kaisha (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006132837-A1 | l-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060247414-A1 | Polyhydroxyalkanoate having vinyl group, ester group, carboxyl group and sulfonic acid group, and production method thereof | CANON KABUSHIKI KAISHA (JP) | 2006-11-02 | — | — | US | disclosed |
| WO-2005121206-A2 | POLYHYDROXYALKANOATE HAVING VINYL GROUP, ESTER GROUP, CARBOXYL GROUP AND SULFONIC ACID GROUP, AND PRODUCTION METHOD THEREOF | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | FABP7 1183/4885FABP5 390/4885CYP2C19 1139/4885 |
| US-20110274655-A1 | TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE | FASN, ACSL1, HSD17B12 | FABP7 380/4885FABP5 79/4885CYP2C19 1203/4885 |
| US-20250223289-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | FABP7 3401/4885FABP5 2911/4885CYP2C19 4574/4885 |
| US-12145935-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | FABP7 3399/4885FABP5 2748/4885CYP2C19 4665/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | FABP7 409/4885FABP5 1986/4885CYP2C19 4779/4885 |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, HRH4 | FABP7 3029/4885FABP5 3377/4885CYP2C19 1573/4885 |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | FABP7 4248/4885FABP5 1626/4885CYP2C19 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.